Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18602981 | PHARMACEUTICAL CAPSULES COMPRISING LUMATEPERONE MONO-TOSYLATE | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18572144 | FREEZE-DRIED LOADED AEROGEL PARTICLES WITH BIOCIDAL PROPERTIES | December 2023 | April 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18512722 | COMBINATION TREATMENT FOR ANTIBIOTIC RESISTANT INFECTIONS | November 2023 | July 2024 | Allow | 8 | 2 | 0 | No | No |
| 18511751 | COMBINATION TREATMENT FOR ANTIBIOTIC RESISTANT INFECTIONS | November 2023 | November 2024 | Abandon | 12 | 0 | 0 | No | No |
| 18504345 | PHARMACEUTICAL CAPSULE COMPOSITIONS COMPRISING LUMATEPERONE MONO-TOSYLATE | November 2023 | May 2024 | Allow | 6 | 1 | 0 | No | No |
| 18478482 | METHODS OF TREATMENT COMPRISING ADMINISTERING LUMATEPERONE MONO-TOSYLATE CAPSULES | September 2023 | June 2025 | Allow | 21 | 2 | 0 | No | No |
| 18367869 | VAGINAL FILMS | September 2023 | July 2025 | Allow | 22 | 3 | 0 | No | No |
| 18449547 | PREPARATION OF OCCLUSIVE DRESSINGS | August 2023 | January 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18225377 | COMPOSITION FOR TREATING OR PREVENTING SKIN PIGMENTATION | July 2023 | June 2025 | Allow | 22 | 2 | 0 | No | No |
| 18331772 | COMPOSITION OF MATTER, SYSTEM, AND METHOD FOR ENHANCED MAGNESIUM UPTAKE, RETENTION, AND SYNERGISTIC ACTIONS | June 2023 | June 2024 | Allow | 12 | 2 | 0 | No | No |
| 18324449 | OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS | May 2023 | October 2023 | Allow | 5 | 1 | 1 | No | No |
| 18141112 | COMPOSITION FOR THE TREATMENT OF REFRACTORY PAINFUL INTERVERTEBRAL DISC RELATED DISORDERS AND METHOD FOR DELIVERY THEREOF TO TREAT THERETO | April 2023 | December 2023 | Allow | 7 | 1 | 0 | No | No |
| 18139434 | GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF | April 2023 | December 2024 | Allow | 20 | 1 | 1 | No | No |
| 18192432 | COMBINATION TREATMENT FOR ANTIBIOTIC RESISTANT INFECTIONS | March 2023 | April 2025 | Abandon | 25 | 4 | 1 | No | No |
| 18184270 | ABUSE-DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE | March 2023 | January 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18109769 | PREPARATION OF OCCLUSIVE DRESSINGS | February 2023 | January 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18108940 | COMPOSITIONS AND METHODS FOR REMEDIATING CHEMICAL WARFARE AGENT EXPOSED SKIN | February 2023 | December 2023 | Allow | 10 | 2 | 0 | No | No |
| 18159756 | HYDROGEL MEMBRANE FOR ADHESION PREVENTION | January 2023 | June 2025 | Allow | 29 | 2 | 0 | No | No |
| 18154695 | PHARMACEUTICAL SPRAY COMPOSITION COMPRISING A VITAMIN D ANALOGUE AND CORTICOSTEROID | January 2023 | March 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18150145 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | January 2023 | April 2024 | Abandon | 15 | 3 | 0 | Yes | No |
| 17986828 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH OXIDATIVE STRESS | November 2022 | March 2025 | Abandon | 28 | 2 | 0 | No | No |
| 17983125 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | November 2022 | March 2025 | Abandon | 28 | 1 | 0 | No | No |
| 17948968 | INGESTIBLE MEDICAL DELIVERY DEVICES | September 2022 | January 2025 | Abandon | 27 | 2 | 0 | No | No |
| 17820325 | COMPOSITION OF MATTER, SYSTEM, AND METHOD FOR ENHANCED MAGNESIUM UPTAKE, RETENTION, AND SYNERGISTIC ACTIONS | August 2022 | March 2023 | Allow | 7 | 1 | 0 | No | No |
| 17885065 | COSMETIC COMPOSITIONS | August 2022 | February 2024 | Allow | 18 | 2 | 0 | No | No |
| 17812832 | NANOPARTICLE DELIVERY SYSTEMS | July 2022 | June 2025 | Abandon | 35 | 2 | 0 | No | No |
| 17861711 | Misoprostol Dispersible Tablet | July 2022 | February 2024 | Allow | 19 | 2 | 0 | No | No |
| 17857442 | STABILIZED TACROLIMUS COMPOSITION | July 2022 | May 2025 | Allow | 34 | 3 | 0 | No | No |
| 17853650 | Topical Compositions For Treating Skin Ailments | June 2022 | November 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17849425 | OPHTHALMIC DRUG DELIVERY | June 2022 | October 2023 | Allow | 15 | 1 | 0 | No | No |
| 17832918 | SCALP PROTECTION COMPOSITION | June 2022 | April 2024 | Allow | 23 | 1 | 0 | No | No |
| 17826069 | DEEP TOPICAL SYSTEMIC NITRIC OXIDE THERAPY APPARATUS AND METHOD | May 2022 | November 2022 | Allow | 6 | 1 | 0 | No | No |
| 17826034 | DEEP TOPICAL SYSTEMIC NITRIC OXIDE THERAPY APPARATUS AND METHOD | May 2022 | November 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17826042 | DEEP TOPICAL SYSTEMIC NITRIC OXIDE THERAPY APPARATUS AND METHOD | May 2022 | December 2022 | Allow | 7 | 1 | 0 | No | No |
| 17826082 | DEEP TOPICAL SYSTEMIC NITRIC OXIDE THERAPY APPARATUS AND METHOD | May 2022 | November 2022 | Allow | 6 | 1 | 0 | No | No |
| 17824516 | NOVEL POVIDONE-IODINE PHARMACEUTICAL PREPARATION AND USES THEREOF | May 2022 | November 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17714465 | Wound-Care Composition and Method of Use | April 2022 | December 2023 | Allow | 20 | 1 | 0 | No | No |
| 17691989 | PROCESSES FOR PREPARING ARIMOCLOMOL CITRATE AND INTERMEDIATES THEREOF | March 2022 | March 2023 | Allow | 12 | 1 | 0 | No | No |
| 17803148 | PERFORMANCE ENHANCEMENT DELIVERY SYSTEM | March 2022 | January 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17687364 | SELF-FUELED PARTICLES FOR PROPULSION THROUGH FLOWING AQUEOUS FLUIDS | March 2022 | October 2024 | Allow | 32 | 2 | 0 | No | No |
| 17674146 | MICRONUTIRENT AND PLANT EXTRACT COMPOSITION AND METHOD OF IMRPOVING BONE HEALTH | February 2022 | August 2022 | Allow | 5 | 1 | 0 | No | No |
| 17673651 | BIOIMPLANT WITH EVANESCENT COATING FILM | February 2022 | February 2024 | Allow | 24 | 2 | 0 | Yes | No |
| 17589838 | PHARMACEUTICAL PREPARATIONS AND METHODS TO MANAGE WEIGHT AND TO MODULATE THE GUT MICROBIOTA | January 2022 | July 2024 | Abandon | 30 | 2 | 0 | Yes | No |
| 17584691 | Dedifferentiated cell extract of Bletilla and method for whitening, anti-oxidation and anti-wrinkling applying the same, and cosmetic comprising the same | January 2022 | March 2025 | Allow | 37 | 3 | 0 | No | No |
| 17582516 | METHODS OF TREATMENT USING PHARMACEUTICAL CAPSULE COMPOSITIONS COMPRISING LUMATEPERONE MONO-TOSYLATE | January 2022 | July 2023 | Allow | 18 | 1 | 0 | No | No |
| 17569715 | COSMETIC COMPOSITIONS AND METHODS | January 2022 | July 2023 | Allow | 18 | 1 | 0 | No | No |
| 17647149 | METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDER | January 2022 | September 2023 | Allow | 21 | 1 | 0 | No | No |
| 17565348 | METHODS AND COMPOSITIONS OF AQUEOUS HYPOBROMOUS ACID FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY CONDITIONS | December 2021 | March 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17561198 | COMPOSITIONS AND METHODS FOR TREATING DISEASES OF THE NAIL | December 2021 | September 2023 | Allow | 20 | 1 | 0 | No | No |
| 17559158 | IMMEDIATE RELEASE ABUSE-DETERRENT GRANULATED DOSAGE FORMS | December 2021 | August 2022 | Allow | 8 | 1 | 0 | No | No |
| 17558179 | TRANSDERMAL PATCHES FOR HANGOVER MINIMIZATION AND/OR RECOCERY, AND/OR SLEEP IMPROVEMENT | December 2021 | September 2024 | Allow | 33 | 2 | 0 | No | No |
| 17549975 | Cosmetic Compositions Comprising Sucrose Esters And Solvents | December 2021 | October 2024 | Allow | 34 | 4 | 0 | No | No |
| 17548931 | ABUSE-DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE | December 2021 | September 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17546645 | POLYMER SYSTEM FOR OPHTHALMIC DRUG DELIVERY | December 2021 | May 2025 | Allow | 41 | 3 | 1 | No | No |
| 17545584 | OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS | December 2021 | June 2022 | Allow | 7 | 1 | 1 | Yes | No |
| 17542282 | METHODS FOR ENHANCED ROOT NODULATION IN LEGUMES | December 2021 | August 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17540649 | BIOBASED, UV-CURABLE NAIL POLISH COMPOSITIONS AND RELATED METHODS | December 2021 | September 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17527528 | Immediate Release Abuse-Deterrent Granulated Dosage Forms | November 2021 | August 2023 | Allow | 21 | 1 | 0 | No | No |
| 17609531 | SUNSCREEN MULTILAYER PARTICLE | November 2021 | March 2024 | Allow | 28 | 2 | 0 | Yes | No |
| 17514388 | ANTIMICROBIAL POLYMER COMPOSITIONS, FIBERS, AND YARNS | October 2021 | March 2024 | Allow | 29 | 2 | 0 | No | No |
| 17507091 | OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS | October 2021 | December 2021 | Allow | 2 | 0 | 0 | Yes | No |
| 17481874 | OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS | September 2021 | March 2022 | Allow | 5 | 2 | 0 | No | No |
| 17411835 | KIDNEY-TARGETING DRUG DELIVERY CARRIER | August 2021 | June 2024 | Abandon | 33 | 2 | 0 | No | No |
| 17346975 | AMORPHOUS CALCIUM CARBONATE FOR TREATING A LEUKEMIA | June 2021 | June 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17413567 | A STABLE CARDIOPLEGIC SOLUTION FOR CARDIAC SURGERY | June 2021 | January 2024 | Allow | 32 | 2 | 0 | Yes | No |
| 17343649 | STABILIZED AND NO2-INHIBITED NITRIC OXIDE GENERATING GELS FOR INHALED NITRIC OXIDE THERAPY | June 2021 | April 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17337649 | Amino Acid Derivatives and Their Uses | June 2021 | September 2023 | Allow | 28 | 1 | 0 | No | No |
| 17337548 | METHOD AND COMPOSITION FOR SELECTIVE TREATMENT OF ANDROGEN RECEPTORS | June 2021 | January 2025 | Allow | 44 | 3 | 0 | No | No |
| 17338248 | TOPICAL FORMULATION AND METHODS FOR PAIN RELIEF | June 2021 | October 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17336148 | COMPOSITIONS AND METHODS FOR IMPROVING THE APPEARANCE OF THE SKIN | June 2021 | February 2025 | Allow | 45 | 3 | 0 | Yes | No |
| 17335981 | TOPICAL COMPOSITION FOR USE IN THE TREATMENT OF BURNS | June 2021 | July 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17298440 | COMPOSITION FOR TREATING OR PREVENTING SKIN PIGMENTATION | May 2021 | November 2023 | Abandon | 30 | 1 | 0 | Yes | No |
| 17332417 | PHARMACEUTICAL CAPSULE COMPOSITIONS COMPRISING LUMATEPERONE MONO-TOSYLATE | May 2021 | February 2023 | Allow | 21 | 1 | 0 | No | No |
| 17327724 | STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOF | May 2021 | November 2024 | Allow | 42 | 4 | 0 | No | No |
| 17326507 | COMPOSITIONS AND METHODS FOR REMEDIATING CHEMICAL WARFARE AGENT EXPOSED SKIN | May 2021 | June 2025 | Allow | 49 | 7 | 1 | Yes | No |
| 17313613 | SKIN CARE COMPOSITIONS AND METHODS | May 2021 | May 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17244910 | METHODS OF TREATING DEGENERATIVE BONE CONDITIONS | April 2021 | November 2024 | Allow | 43 | 3 | 0 | No | No |
| 17244552 | PATCH WITH DMSO IN ADHESIVE LAYER | April 2021 | June 2023 | Allow | 26 | 3 | 0 | Yes | No |
| 17238278 | METHOD AND SYSTEM FOR DRUG DELIVERY | April 2021 | April 2023 | Allow | 24 | 1 | 0 | No | No |
| 17234432 | PREPARATION OF OCCLUSIVE DRESSINGS | April 2021 | April 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17220479 | METHOD FOR TREATMENT OF A VIRAL-MEDIATED INFECTIOUS DISEASE | April 2021 | April 2023 | Allow | 25 | 1 | 0 | Yes | No |
| 17219800 | COMPOSITIONS AND METHODS FOR STYLING THE HAIR | March 2021 | April 2025 | Allow | 48 | 4 | 0 | Yes | No |
| 17218628 | COOLING SPRAY | March 2021 | April 2023 | Allow | 24 | 2 | 0 | Yes | No |
| 17217320 | HOMEOPATHIC NASAL GEL, SWAB, AND SPRAY FORMULATIONS | March 2021 | March 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17213561 | Therapeutic Detoxification Compositions and Methods of Making and Using Same | March 2021 | September 2023 | Allow | 29 | 1 | 0 | No | No |
| 17212380 | COMPOSITION FOR THE TREATMENT OF NAIL FUNGUS | March 2021 | January 2025 | Allow | 45 | 6 | 0 | Yes | No |
| 17211274 | OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS | March 2021 | September 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 17194587 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A CHEMOKINE/CHEMOKINE RECEPTOR INHIBITOR | March 2021 | January 2024 | Abandon | 34 | 2 | 0 | No | No |
| 17194832 | TOPICAL IMMUNOSENSITIZERS TO TREAT VIRAL AND FUNGAL INFECTIONS | March 2021 | December 2023 | Allow | 33 | 2 | 0 | Yes | No |
| 17273855 | IRON CHELATORS FOR TREATING AESTHETIC SKIN CONDITIONS | March 2021 | April 2024 | Abandon | 38 | 3 | 0 | No | No |
| 17187982 | FRAGRANCE MATERIALS | March 2021 | August 2023 | Allow | 29 | 2 | 0 | No | No |
| 17184713 | POROUS MEDICAL DEVICE AND METHODS OF USE | February 2021 | April 2024 | Allow | 38 | 3 | 1 | No | No |
| 17183076 | EXTENDED-RANGE SPRAY APPLICATOR | February 2021 | October 2023 | Allow | 32 | 1 | 1 | No | No |
| 17175082 | OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS | February 2021 | July 2021 | Allow | 5 | 2 | 0 | No | No |
| 17171399 | COSMETIC COMPOSITION COMPRISING EXOSOMES DERIVED FROM GALACTOMYCES AS ACTIVE INGREDIENT | February 2021 | October 2022 | Allow | 21 | 1 | 0 | No | No |
| 17167265 | TRACE ELEMENTS | February 2021 | August 2024 | Allow | 42 | 4 | 0 | Yes | No |
| 17166624 | Ozone Foam for Treating Dermatitis | February 2021 | January 2024 | Abandon | 36 | 2 | 0 | Yes | No |
| 17162118 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | January 2021 | June 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17157118 | BICARBONATE AS A POTENTIATOR FOR ANTIMICROBIAL AGENTS | January 2021 | May 2023 | Allow | 28 | 1 | 0 | No | No |
| 17259732 | TOPICAL DETOMIDINE FORMULATIONS | January 2021 | April 2024 | Abandon | 39 | 3 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner STEVENS, MARK V.
With a 16.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 15.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner STEVENS, MARK V works in Art Unit 1613 and has examined 805 patent applications in our dataset. With an allowance rate of 65.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 25 months.
Examiner STEVENS, MARK V's allowance rate of 65.7% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by STEVENS, MARK V receive 2.29 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by STEVENS, MARK V is 25 months. This places the examiner in the 64% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +45.6% benefit to allowance rate for applications examined by STEVENS, MARK V. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 24.0% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 49.3% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 75.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 58% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 81.2% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 88.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 61.1% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 46% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.8% of allowed cases (in the 75% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.